Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

被引:0
作者
A Shimoni
S T Zwas
Y Oksman
I Hardan
N Shem-Tov
A Rand
R Yerushalmi
A Avigdor
I Ben-Bassat
A Nagler
机构
[1] Chaim Sheba Medical Center,The Division of Hematology and Bone Marrow Transplantation
[2] Chaim Sheba Medical Center,The Department of Nuclear Medicine
来源
Bone Marrow Transplantation | 2008年 / 41卷
关键词
non-Hodgkin's lymphoma; reduced-intensity conditioning; radioimmunotherapy; ibritumomab tiuxetan; GVHD;
D O I
暂无
中图分类号
学科分类号
摘要
Allogeneic SCT is an effective therapy for lymphoma. Reduced-intensity conditioning (RIC) reduces non-relapse mortality (NRM) associated with myeloablative conditioning but relapse rates are high when performed in active disease. This study was designed to explore the safety and outcome of ibritumomab tiuxetan (Zevalin) combined with RIC in patients with advanced lymphoma. The study included 12 patients, median age 54 years (37–62), with a median of four prior treatments (2–6) and active disease documented on PET–CT. Zevalin 0.4 mCi/kg was given on day −14 and fludarabine combined with BU (n=6) or melphalan (n=6) was started on day −6. GVHD prevention was tapered 3 months after SCT to augment the graft-versus-lymphoma effect. All patients engrafted, a median of 14 days after SCT. Eighty-three percent achieved CR/PR. With a median follow-up of 21 months (12–37), 2-year PFS is 33%. Only three patients relapsed; cumulative incidence 25%. NRM was 42%, predominantly due to acute GVHD. Zevalin–RIC is feasible with consistent engraftment, acceptable organ toxicity, but high rates of acute GVHD. The low incidence of relapse suggests augmented anti-lymphoma effect. Zevalin–RIC merits further study. Better results may be achieved in patients earlier in disease course and with longer duration of immune-suppression.
引用
收藏
页码:355 / 361
页数:6
相关论文
共 213 条
  • [1] Philip T(1995)Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1540-1545
  • [2] Guglielmi C(1987)High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma N Engl J Med 316 1493-1498
  • [3] Hagenbeek A(1999)International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury J Clin Oncol 17 423-429
  • [4] Somers R(2005)The graft-versus-lymphoma effect: clinical review and future opportunities Bone Marrow Transplant 36 1-17
  • [5] Van der Lelie H(2002)Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 4310-4316
  • [6] Bron D(1998)Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma Blood 91 1178-1184
  • [7] Philip T(1991)Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 649-653
  • [8] Armitage JO(2000)Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy Br J Haematol 111 18-29
  • [9] Spitzer G(2000)Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma Bone Marrow Transplant 25 1021-1028
  • [10] Chauvin F(1998)Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 2817-2824